Loading...
XSWXHBMN
Market cap1.33bUSD
Dec 20, Last price  
174.60CHF
1D
-0.23%
1Q
-0.46%
Jan 2017
76.36%
IPO
112.93%
Name

HBM Healthcare Investments AG

Chart & Performance

D1W1MN
XSWX:HBMN chart
P/E
P/S
862.41
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
-63.51%
Revenues
3m
P
103,361,000136,416,0000213,517,000110,246,00090,054,000-34,908,000-18,674,00070,385,000356,782,000260,907,00025,930,000139,986,000118,653,000213,069,000186,189,000766,308,000-76,500,000-144,897,0002,982,000
Net income
-1m
L-99.26%
57,531,000144,825,300150,896,000222,304,000-312,880,00066,033,000-56,382,000-22,169,00067,005,000353,522,000257,511,00023,089,000136,772,000115,874,000209,067,000182,698,000756,271,000-78,031,000-146,318,000-1,083,000
CFO
-2m
L+32.38%
35,042,000-58,735,00011,551,00038,886,00026,737,000-16,424,000-17,171,000-14,069,00067,005,000353,522,000257,511,00023,089,000136,772,000115,874,000-2,852,000-4,158,000-3,226,000-10,197,000-1,288,000-1,705,000
Dividend
Aug 07, 20247.5 CHF/sh
Earnings
Jan 20, 2025

Profile

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.
IPO date
Feb 14, 2008
Employees
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
2,982
-102.06%
(144,897)
89.41%
(76,500)
-109.98%
Cost of revenue
1,604
1,095
1,166
Unusual Expense (Income)
NOPBT
1,378
(145,992)
(77,666)
NOPBT Margin
46.21%
100.76%
101.52%
Operating Taxes
(2,644)
(237)
Tax Rate
NOPAT
1,378
(143,348)
(77,429)
Net income
(1,083)
-99.26%
(146,318)
87.51%
(78,031)
-110.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
(66,498)
(67,484)
(86,964)
BB yield
4.96%
4.53%
4.53%
Debt
Debt current
49,978
148,920
Long-term debt
99,389
149,186
148,920
Deferred revenue
151,359
150,965
Other long-term liabilities
(99,389)
(49,978)
(148,920)
Net debt
(1,707,119)
(1,724,867)
(1,839,595)
Cash flow
Cash from operating activities
(1,705)
(1,288)
(10,197)
CAPEX
Cash from investing activities
125,000
71,500
50,000
Cash from financing activities
(118,800)
(69,868)
(40,448)
FCF
1,318
3,547
(228,899)
Balance
Cash
10,227
5,732
5,388
Long term investments
1,796,281
1,918,299
2,132,047
Excess cash
1,806,359
1,931,276
2,141,260
Stockholders' equity
1,719,856
3,411,017
3,771,215
Invested Capital
86,712
141,957
145,115
ROIC
1.21%
ROCE
0.08%
EV
Common stock shares outstanding
6,932
6,957
6,957
Price
193.60
-9.53%
214.00
-22.46%
276.00
-16.99%
Market cap
1,342,035
-9.86%
1,488,798
-22.46%
1,920,132
-16.99%
EV
(365,084)
1,401,858
1,864,860
EBITDA
1,378
(145,992)
(77,666)
EV/EBITDA
Interest
1,697
2,649
2,717
Interest/NOPBT
123.15%